The actual pump sits on or next to heart’s left ventricle with a tube attached that routes the blood to aorta. A cable called driveline extends from the pump, out through the skin, and connects the pump to a controller and power sources worn outside the body. Ventricular assist devices are used in those patients who are suffering with class III and class IV advanced heart diseases as per New York Heart Association (NYHA) and patients who are awaiting for not suitable for heart transplantation.
Some of the key driving factors attributing to the growth of this include increasing number of patients with cardiovascular diseases such as hypertension, heart failures and coronary artery diseases, and shortage of number of heart donors. In addition, changing lifestyle, alcohol consumption, growing obesity and smoking further propelling the market growth, as these factors increase the bold glucose and lipid levels, which results in serious cardiovascular diseases.
According to American Heart Association publication, it has been estimated that in the US alone approximately 5.5 million people suffered from heart failure in 2013 and 300,000 die each year because of heart failure. The market for LVAD is expected to reach around USD 1.9 billion by 2022, growing at a CAGR of 17.3% during the forecast period of 2016e to 2022f. However, there are certain restraining factors which could hamper the growth of the market, which includes, high costs associated with the LAVD implantation compared to other therapies available for CVD diseases.
Geographically, North America is leading contributor to the market and is expected to retain its position during the forecast period. Nonetheless, the market for Asia-Pacific region is expected to grow at a faster rate owing to increasing prevalence of CVD diseases, growing awareness among the population, improving healthcare infrastructure, rise in healthcare spending, and favorable government policies.
The report delivers a strategic analysis of the global market for LVADs and growth forecast for the period from 2016e - 2022f. The scope of the report includes competitive analysis of various market players who are operating in the market, segmental analysis based on type of indication. It also covers geographical analysis of the market with growth forecast for the period of 2016e - 2022f. The Porter’s Five Forces analysis and value chain analysis included in the report provides an insight into market dynamics and industry competition.
The study also provides information for recent merger and acquisition deals happened in the global LVAD market. Moreover, the report also includes growth strategies and entry barriers to be considered to cater to the exact business opportunities in this market. Additionally, to aid in strategic decision making, the report also includes competitive profiling of leading players, recent developments in the industry and various business strategies adopted by them. This report will help players in global LVAD market to plan and implement their strategies in different market areas such as emerging geographies, and new technologies
The company profile section include detailed analysis of some of the key players such as Abiomed, Heart Ware International Inc., St Jude Medical, Berlin Heart GmbH, Apaxis, Inc., Jarvik Heart Inc., and CorWave.
1.1.1 Report description
1.1.2 Research methodology
1.1.3 List of abbreviations
1.1.4 Market segmentation
1.2 Executive summary
1.3 Qualitative analysis
1.3.1 Market overview
1.3.2 Value chain analysis
1.3.3 Porters five forces analysis
1.3.4 Key M&A trends and strategic partnerships
1.3.5 Competitive matrix of the key companies
1.4 Global LVAD market, by type of indication, 2014-2022f
1.4.1 Destination therapy
1.4.2 Bridge to destination
1.4.3 Bridge to recovery
1.4.4 Bridge to transplantation
1.5 Global LVAD market, by geography, 2014-2022f
1.5.1 North America
1.5.4 Rest of the World
1.6 Company profiles
1.6.2 Heart Ware International Inc. (acquired by Medtronic plc)
1.6.3 Thoratec Corporation (acquired by St. Jude Medical Inc.)
1.6.4 Berlin Heart GmbH
1.6.5 Apaxis, Inc.
1.6.6 Jarvik Heart Inc.
1.6.9 Evaheart, Inc.